Listening to the Patient: Improving the Design and Conduct of Clinical Trials in Inflammatory Bowel Diseases
Open Access
- 1 January 2020
- journal article
- letter
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 2 (1), otaa011
- https://doi.org/10.1093/crocol/otaa011
Abstract
There is an urgent need for new treatments for inflammatory bowel diseases, but it’s hard to enroll the large number of patients needed for clinical trials. Making trials more patient-friendly by giving patients a voice would help solve this problem.Keywords
Funding Information
- Genentech
This publication has 16 references indexed in Scilit:
- Precision Medicine in Hormone Receptor-Positive Breast CancerFrontiers in Oncology, 2018
- Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome SetClinical Gastroenterology and Hepatology, 2018
- Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic ReviewClinical Gastroenterology and Hepatology, 2018
- Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi surveyBMJ Open, 2017
- Patient participation in cancer clinical trials: A pilot test of lay navigationContemporary Clinical Trials Communications, 2016
- Ethical considerations for clinical trials in inflammatory bowel disease.2014
- Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient PopulationClinical Gastroenterology and Hepatology, 2012
- Community Involvement in HIV and Tuberculosis ResearchJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2005
- How have patient advocates in the United States benefited cancer research?Nature Reviews Cancer, 2005